| | Variables | Training Group (n = 4456) | Testing Group (n = 4541) |
| | Age, years, n (%) | | <65 | 1700 (38.15) | 1735 (38.21) | | 65–80 | 2017 (45.26) | 2059 (45.34) | | ≥81 | 739 (16.58) | 747 (16.45) | | Gender, n (%) | | Male | 2557 (57.38) | 2600 (57.26) | | Female | 1899 (42.62) | 1941 (42.74) | | Race, n (%) | | White | 2558 (57.41) | 2612 (57.52) | | Black | 726 (16.29) | 737 (16.23) | | Others | 1172 (26.30) | 1192 (26.25) | | Marital status, n (%) | | Married | 2722 (61.09) | 2775 (61.11) | | Widowed | 663 (14.88) | 673 (14.82) | | Others | 1071 (24.04) | 1093 (24.07) | | Primary site, n (%) | | Fundus | 164 (3.68) | 166 (3.66) | | Body of stomach | 629 (14.12) | 641 (14.12) | | Antrum | 1649 (37.01) | 1673 (36.84) | | Pylorus | 228 (5.12) | 236 (5.20) | | Lesser curvature | 671 (15.06) | 685 (15.08) | | Greater curvature | 248 (5.57) | 255 (5.62) | | Overlapping lesion | 478 (10.73) | 487 (10.72) | | Stomach or NOS | 389 (8.73) | 398 (8.76) | | AJCC stage, n (%) | | I | 1223 (27.45) | 1232 (27.13) | | II | 1144 (25.67) | 1168 (25.72) | | III | 1632 (36.62) | 1677 (36.93) | | IV | 457 (10.26) | 464 (10.22) | | T stage, n (%) | | T1 | 997 (22.37) | 1008 (22.20) | | T2 | 580 (13.02) | 586 (12.90) | | T3 | 1436 (32.23) | 1465 (32.26) | | T4 | 1443 (32.38) | 1482 (32.64) | | N stage, n (%) | | N0 | 1785 (40.06) | 1801 (39.66) | | N1 | 825 (18.51) | 847 (18.65) | | N2 | 792 (17.77) | 811 (17.86) | | N3 | 1054 (23.65) | 1082 (23.83) | | M stage, n (%) | | M0 | 3999 (89.74) | 4077 (89.78) | | M1 | 457 (10.26) | 464 (10.22) | | Tumor size, cm, n (%) | | ≤4 | 2166 (48.61) | 2209 (48.65) | | >4 | 2290 (51.39) | 2332 (51.35) | | Insurance, n (%) | | Any Medicaid | 905 (20.31) | 929 (20.46) | | Insured | 2708 (60.77) | 2755 (60.67) | | No specific insured | 694 (15.57) | 707 (15.57) | | Uninsured | 149 (3.34) | 150 (3.30) | | Surgery, n (%) | | Yes | 4419 (99.17) | 4503 (99.16) | | No | 37 (0.83) | 38 (0.84) | | Radiation, n (%) | | Yes | 1126 (25.27) | 1214 (26.73) | | No | 3330 (74.73) | 3327 (73.27) | | Chemotherapy, n (%) | | Yes | 2245 (50.38) | 2288 (50.39) | | No | 2211 (49.62) | 2253 (49.61) | | Grade, n (%) | | I | 236 (5.30) | 239 (5.26) | | II | 1113 (24.98) | 1137 (25.04) | | III | 3001 (67.35) | 3057 (67.32) | | IV | 106 (2.38) | 108 (2.38) | | Vital status, n (%) | | Alive | 2461 (55.23) | 2508 (55.23) | | Dead | 1995 (44.77) | 2033 (44.77) | | Regional nodes positive (M (Q1, Q3)) | 1 (0, 6) | 1 (0, 6) | | Follow-up time, months (M (Q1, Q3)) | 20.0 (11.0, 35.0) | 20.0 (11.0, 35.0) |
|
|
